[5-12]Dramatic improvements in process economy with column/non-column purification for monoclonal antibody production

报告题目：Dramatic improvements in process economy with column/non-column purification for monoclonal antibody production

报 告 人：年锐 博士（BTI, A*STAR, Singapore）

报告时间：2014年5月12日（星期一）下午2:00

报告地点：独墅湖校区二期云轩楼2301室

报告摘要

Protein A in columns has been proven effective as a capture step for therapeutic IgG, but it imposes a productivity bottleneck that compounds its already-substantial expense. In our study, we show data from new clarification methods that enable a number of non-protein A capture alternatives, including non-column formats. Data include results from a magnetic nanoparticle version of steric exclusion chromatography that achieves 1000 times higher capacity per mL of particles than protein A in columns. We also show data from a breakthrough convection-based system that supports 10-fold lower host protein, aggregate and DNA content, plus 10-20% higher IgG recovery compared to 3-step protein A platforms. And it achieves these results with two thirds less water than current protein A platforms.

报告人简介

Dr. Nian Rui is a research scientist at Downstream Processing Group in Bioprocessing Technology Institute (BTI, A*STAR, Singapore). He is currently focusing on the development of next generation bioseparation technology and a key member of Trinity Project (S$18 million, funded by ETPL, Singapore), which represents a network of novel fractionation technologies designed to overcome the economic, performance and productivity limitations of current manufacturing technology for purification of recombinant proteins and vaccines.  His research activities span a wide range of areas from some fresh approaches for cell harvest clarification to non-chromatographic methods for IgG purification, which essentially cover all the monoclonal antibody manufacturing process. Several 1 or 2-step purification platforms with high productivity and low operation cost are under evaluation, which can be alternatives to current 3 or 4 steps antibody processing used for standard biopharmaceuticals.

Prior to joining BTI in 2012, Dr. Nian was the lead scientist at A-Bio Pharma (Singapore). In this role, he mainly took in charge of the downstream process development of various biosimilars in lab-scale and also led the pilot-scale purification (from up to 200 L cell harvest).

Dr. Nian earned a PhD degree in Chemical and Biomolecular Engineering from National University of Singapore in 2008. After that he conducted his post-doctoral research in Sungkyunkwan University (South Korea) and in Temasek Life Sciences Laboratory (Singapore).